A Pilot Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Pharmacodynamics
- 12 Dec 2017 Updated results will be presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 12 Dec 2017 Results (n=8) assessing effect of Ibrutinib on BTK occupancy and B-cell receptor (BCR) signaling presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 19 Jun 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.